Amgen Smashes Q2 Estimates, Raises Full-Year Guidance

Amgen Inc. (AMGN) has reported a strong second quarter, beating revenue and EPS estimates.

The company's commercial portfolio, driven by Repatha, Uplizna, Evenity, Tezspire, and Imdelltra, continues to outperform expectations despite $7 billion in LOE headwinds.

Amgen has raised its full-year revenue guidance by $1 billion and EPS guidance by $0.50, with key pipeline catalysts including MariTide and olpasiran phase 3 readouts expected in 2027-2028.

The company's net debt of $43.3 billion limits major M&A activity, but in-licensing and bolt-on deals remain viable options.